Study of a gene marker in newly diagnosed ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study looks at a specific gene (CircDENND4C) in tumor samples from women newly diagnosed with ovarian cancer, before any treatment or surgery. It aims to understand if this gene can help predict how the cancer behaves or responds to treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have been recently diagnosed with ovarian cancer at South Egypt Cancer Institute.
- You must not have had surgery for your cancer yet.
- You must not have received any anti-cancer treatment (like chemotherapy or radiation) before joining.
- You must not have any other cancer or chronic disease that could affect the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at certain substances in the body (called metabolic biomarkers) and how they relate to how well patients do after treatment. It is for women who have just been diagnosed with high-grade serous ovarian cancer and have not yet had any treatment.
This study looks for cancer DNA in your blood to understand advanced ovarian cancer better. It helps doctors see how the disease changes over time and may improve future treatments.
This study looks at genetic changes in ovarian cancer to find possible targeted treatments. It may help you if you have certain types of ovarian cancer and are seeking more personalized care.
This study is testing new blood tests that might help detect ovarian cancer earlier by looking for specific markers. It involves people with suspected ovarian cancer and healthy volunteers, and aims to improve how we diagnose the disease.
This study looks at metastatic ovarian cancer by analyzing many types of patient data (from “multi-omics,” which means different kinds of lab and biological information). It may help doctors better understand the disease and improve future care.
This study looks at tumor tissue from ovarian cancer patients to find “biomarkers,” or lab signals, that may predict how the disease behaves or how it might respond to treatment. You may be asked for a biopsy of the relapsed (coming back) tumor or to use an existing archived tumor sample.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.